Upload
gtarunreddy
View
408
Download
1
Embed Size (px)
Citation preview
INVESTIGATIONAL NEW DRUG&
NEW DRUG APPLICATION
1
DRUG DEVELOPMENT
Development of a new therapeutic drug is a complex, lengthy andexpensive process
2
expensive process
costs nearly huge amount andan average of 15 years.
3
Introduction• Investigational new drug (IND)
It’s deals with a new chemical entity, which will be tested for obtaining evidence of safety and effectiveness in accordance with the regulations.
• New drug application (NDA)
Is a document submitted to the regulatory authorities for permission to market a new drug product in that country.
4
Investigational new drug (IND)
5
To assure the safety and rights of subjects in all phases of an investigation.
In phases 2 and 3, to help assure that the quality of the scientific evaluation of the drug
Objectives
quality of the scientific evaluation of the drug according to the -- (21 CFR 312.22).
• Code of Federal Regulations, part 312 (21 CFR part 312) (the IND regulations).
6
TYPES OF IND Investigator IND
o Submitted by a physician who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed.
o Physician might submit a research IND to propose studying an unapproved drug, or an approved product for a new indication or in a new patient population.
Emergency Use IND
7
Emergency Use IND
o Allows FDA to authorize use of an experimental drug in an emergency situation .
o Does not allow time for submission of an IND in accordance with 21CFR , Sec. 312.23 or Sec. 312.34
Treatment IND
o Submitted for experimental drugs showing promise in clinical testing for serious or immediately life-threatening conditions while the final clinical work is conducted and the FDA review takes place.
The IND application must contain :-
• In - vitro studies.
• Toxicology Studies.
• Chemical studies.
• Manufacturing Information .
• Clinical trail protocols.
• A review given by the institutional review board (IRB)
8
Applicant\Drug Sponsor
IND
Review by CDER
Medicinal chemistry Pharmacological \ Toxicological statistical
Safety Review Sponsor submits new data
Safety acceptable for Chemical hold decisionNoSafety acceptable forstudy to proceed
Chemical hold decision
Complete reviews Notify Sponsor
Review complete & acceptable? Sponsor notified of deficiencies
No Deficiencies Study ongoing
No
No
NoYes
Yes
Yes
Investigational New Drug Application (IND)
10Investigational New Drug Application (IND) in INDIA
New drug application(NDA)
11
(NDA)
Provide enough information to permit FDA reviewers to establish the following:
Safety & effectiveness of drug.
Benefits overweigh risks.
Risk Benefit
OBJECTIVES
12
Is the drug’s proposed labelling (package insert) appropriate, and what should it contain?
Are the methods used in manufacturing (Good Manufacturing Practice, GMP) the drug and the controls used to maintain the drug’s quality adequate to preserve the drug’s identity, strength, quality, and purity?
NDA CONTENTS1. Introduction
Brief description of the drug and the therapeutic class to which it belongs
2. Chemical and pharmaceutical information
3. Animal Pharmacology
4. Animal Toxicology
5. Human/Clinical Pharmacology phase I
6. Therapeutic exploratory trials (Phase II)
13
6. Therapeutic exploratory trials (Phase II)
7. Therapeutic confirmatory trials (Phase III)
8. Special Studies
o Geriatrics, pediatrics, pregnant or nursing women
9. Regulatory status in other countries
10. Prescribing information
11. Samples and Testing Protocol/s
When to get approval from NDA
14
CLINICAL TRAIL PHASES
15
Review of NDA process
16
Requirements US INDIA
Application ANDA\NDA MAA
Debarment Classification
Required Required
Number ofcopies
3 1
Approval ~18 Months 12~18 Months
ADMINISTRATIVE REQUIREMENTSADMINISTRATIVE REQUIREMENTS
Approval Time period
~18 Months 12~18 Months
Fees Approximately$52,000 for
ANDA Application &
Up to $2 million for NDA Application
50,000 INR
Presentation eCTD & Paper Paper
Requirements US INDIA
Justification ICH Q6A ICHQ6A
Assay 90-100% 90-110%
Disintegration Not Required Required
Colour Identification Not Required Required
18
Water Content Required Required
REFERENCES
21 CFR.org
www.Wikipedia.org
www.Cdsco.com
Drug regulatory affairs by thimasetty.Drug regulatory affairs by thimasetty.
http://www.fda.gov/
http://www.medicalnewstoday.com/artes/172522.php
19
20